Abstract
HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population.
Original language | English (US) |
---|---|
Pages (from-to) | 1028-1030 |
Number of pages | 3 |
Journal | American journal of public health |
Volume | 103 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2013 |
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health